{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["NASH", "autoimmune diseases", "metabolic disorders", "nuclear receptors", "ursolic acid"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37893218", "DateRevised": {"Year": "2023", "Month": "10", "Day": "30"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "10", "Day": "19"}], "Language": ["eng"], "ELocationID": ["2845", "10.3390/biomedicines11102845"], "Journal": {"ISSN": "2227-9059", "JournalIssue": {"Volume": "11", "Issue": "10", "PubDate": {"Year": "2023", "Month": "Oct", "Day": "19"}}, "Title": "Biomedicines", "ISOAbbreviation": "Biomedicines"}, "ArticleTitle": "Overview of Ursolic Acid Potential for the Treatment of Metabolic Disorders, Autoimmune Diseases, and Cancers via Nuclear Receptor Pathways.", "Abstract": {"AbstractText": ["Nuclear receptors (NRs) form a family of druggable transcription factors that are regulated by ligand binding to orchestrate multifaceted physiological functions, including reproduction, immunity, metabolism, and growth. NRs represent attractive and valid targets for the management and treatment of a vast array of ailments. Pentacyclic triterpenes (PTs) are ubiquitously distributed natural products in medicinal and aromatic plants, of which ursolic acid (UA) is an extensively studied member, due to its diverse bio-pertinent activities against different cancers, inflammation, aging, obesity, diabetes, dyslipidemia, and liver injury. In fact, PTs share a common lipophilic structure that resembles NRs' endogenous ligands. Herein, we present a review of the literature on UA's effect on NRs, showcasing the resulting health benefits and potential therapeutic outcomes. De facto, UA exhibited numerous pharmacodynamic effects on PPAR, LXR, FXR, and PXR, resulting in remarkable anti-inflammatory, anti-hyperlipidemic, and hepatoprotective properties, by lowering lipid accumulation in hepatocytes and mitigating non-alcoholic steatohepatitis (NASH) and its subsequent liver fibrosis. Furthermore, UA reversed valproate and rifampicin-induced hepatic lipid accumulation. Additionally, UA showed great promise for the treatment of autoimmune inflammatory diseases such as multiple sclerosis and autoimmune arthritis by antagonizing ROR\u03b3. UA exhibited antiproliferative effects against skin, prostate, and breast cancers, partially via PPAR\u03b1 and ROR\u03b3 pathways. Herein, for the first time, we explore and provide insights into UA bioactivity with respect to NR modulation."]}, "AuthorList": [{"Identifier": ["0000-0001-8077-3668"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Faculty of Science, University of Bisha, P.O. Box 551, Bisha 61922, Saudi Arabia."}], "LastName": "Kadasah", "ForeName": "Sultan F", "Initials": "SF"}, {"Identifier": ["0000-0002-9220-2659"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan."}], "LastName": "Radwan", "ForeName": "Mohamed O", "Initials": "MO"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Biomedicines", "NlmUniqueID": "101691304", "ISSNLinking": "2227-9059"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Chen T. Nuclear receptor drug discovery. Curr. Opin. Chem. Biol. 2008;12:418\u2013426. doi: 10.1016/j.cbpa.2008.07.001.", "ArticleIdList": ["10.1016/j.cbpa.2008.07.001", "18662801"]}, {"Citation": "Burris T.P., Solt L.A., Wang Y., Crumbley C., Banerjee S., Griffett K., Lundasen T., Hughes T., Kojetin D.J. Nuclear receptors and their selective pharmacologic modulators. Pharmacol. Rev. 2013;65:710\u2013778. doi: 10.1124/pr.112.006833.", "ArticleIdList": ["10.1124/pr.112.006833", "23457206"]}, {"Citation": "Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Sch\u00fctz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor superfamily: The second decade. Cell. 1995;83:835\u2013839. doi: 10.1016/0092-8674(95)90199-X.", "ArticleIdList": ["10.1016/0092-8674(95)90199-X", "PMC6159888", "8521507"]}, {"Citation": "Cai W., Yang T., Liu H., Han L., Zhang K., Hu X., Zhang X., Yin K.-J., Gao Y., Bennett M.V., et al. Peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3): A master gatekeeper in CNS injury and repair. Prog. Neurobiol. 2018;163\u2013164:27\u201358. doi: 10.1016/j.pneurobio.2017.10.002.", "ArticleIdList": ["10.1016/j.pneurobio.2017.10.002", "PMC6037317", "29032144"]}, {"Citation": "Frigo D.E., Bondesson M., Williams C. Nuclear receptors: From molecular mechanisms to therapeutics. Essays Biochem. 2021;65:847\u2013856. doi: 10.1042/EBC20210020.", "ArticleIdList": ["10.1042/EBC20210020", "PMC8628184", "34825698"]}, {"Citation": "Fang Y., Hegazy L., Finck B.N., Elgendy B. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. J. Med. Chem. 2021;64:17545\u201317571. doi: 10.1021/acs.jmedchem.1c01017.", "ArticleIdList": ["10.1021/acs.jmedchem.1c01017", "34889100"]}, {"Citation": "Lith S.C., de Vries C.J.M. Nuclear receptor Nur77: Its role in chronic inflammatory diseases. Essays Biochem. 2021;65:927\u2013939. doi: 10.1042/EBC20210004.", "ArticleIdList": ["10.1042/EBC20210004", "34328179"]}, {"Citation": "Penvose A., Keenan J.L., Bray D., Ramlall V., Siggers T. Comprehensive study of nuclear receptor DNA binding provides a revised framework for understanding receptor specificity. Nat. Commun. 2019;10:2514. doi: 10.1038/s41467-019-10264-3.", "ArticleIdList": ["10.1038/s41467-019-10264-3", "PMC6555819", "31175293"]}, {"Citation": "Pan P., Chen X. Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia. Cells. 2020;9:1921. doi: 10.3390/cells9091921.", "ArticleIdList": ["10.3390/cells9091921", "PMC7563802", "32824945"]}, {"Citation": "Forman B.M., Ruan B., Chen J., Schroepfer G.J., Evans R.M. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. USA. 1997;94:10588\u201310593. doi: 10.1073/pnas.94.20.10588.", "ArticleIdList": ["10.1073/pnas.94.20.10588", "PMC23411", "9380679"]}, {"Citation": "Gigu\u00e8re V. Orphan nuclear receptors: From gene to function. Endocr. Rev. 1999;20:689\u2013725. doi: 10.1210/er.20.5.689.", "ArticleIdList": ["10.1210/er.20.5.689", "10529899"]}, {"Citation": "Kliewer S.A., Lehmann J.M., Willson T.M. Orphan nuclear receptors: Shifting endocrinology into reverse. Science. 1999;284:757\u2013760. doi: 10.1126/science.284.5415.757.", "ArticleIdList": ["10.1126/science.284.5415.757", "10221899"]}, {"Citation": "Kumar N., Solt L.A., Conkright J.J., Wang Y., Istrate M.A., Busby S.A., Garcia-Ordonez R.D., Burris T.P., Griffin P.R. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol. Pharmacol. 2010;77:228\u2013236. doi: 10.1124/mol.109.060905.", "ArticleIdList": ["10.1124/mol.109.060905", "PMC2812071", "19887649"]}, {"Citation": "Yang C., Li Q., Li Y. Targeting Nuclear Receptors with Marine Natural Products. Mar. Drugs. 2014;12:601\u2013635. doi: 10.3390/md12020601.", "ArticleIdList": ["10.3390/md12020601", "PMC3944506", "24473166"]}, {"Citation": "Hiebl V., Ladurner A., Latkolik S., Dirsch V.M. Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR. Biotechnol. Adv. 2018;36:1657\u20131698. doi: 10.1016/j.biotechadv.2018.03.003.", "ArticleIdList": ["10.1016/j.biotechadv.2018.03.003", "29548878"]}, {"Citation": "She J., Gu T., Pang X., Liu Y., Tang L., Zhou X. Natural Products Targeting Liver X Receptors or Farnesoid X Receptor. Front. Pharmacol. 2021;12:772435. doi: 10.3389/fphar.2021.772435.", "ArticleIdList": ["10.3389/fphar.2021.772435", "PMC8766425", "35069197"]}, {"Citation": "Krasowski M.D., Ni A., Hagey L.R., Ekins S. Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol. Cell Endocrinol. 2011;334:39\u201348. doi: 10.1016/j.mce.2010.06.016.", "ArticleIdList": ["10.1016/j.mce.2010.06.016", "PMC3033471", "20615451"]}, {"Citation": "Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell. 1995;83:841\u2013850. doi: 10.1016/0092-8674(95)90200-7.", "ArticleIdList": ["10.1016/0092-8674(95)90200-7", "8521508"]}, {"Citation": "Sever R., Glass C.K. Signaling by Nuclear Receptors. Cold Spring Harb. Perspect. Biol. 2013;5:a016709. doi: 10.1101/cshperspect.a016709.", "ArticleIdList": ["10.1101/cshperspect.a016709", "PMC3578364", "23457262"]}, {"Citation": "Zhang Y., Luo X., Wu D., Xu Y. ROR nuclear receptors: Structures, related diseases, and drug discovery. Acta Pharmacol. Sin. 2015;36:71\u201387. doi: 10.1038/aps.2014.120.", "ArticleIdList": ["10.1038/aps.2014.120", "PMC4571318", "25500868"]}, {"Citation": "Newman D.J., Cragg G.M. Natural Products as Sources of New Drugs from 1981 to 2014. J. Nat. Prod. 2016;79:629\u2013661. doi: 10.1021/acs.jnatprod.5b01055.", "ArticleIdList": ["10.1021/acs.jnatprod.5b01055", "26852623"]}, {"Citation": "Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005;4:206\u2013220. doi: 10.1038/nrd1657.", "ArticleIdList": ["10.1038/nrd1657", "15729362"]}, {"Citation": "Seo D.Y., Lee S.R., Heo J.-W., No M.-H., Rhee B.D., Ko K.S., Kwak H.-B., Han J. Ursolic acid in health and disease. Korean J. Physiol. Pharmacol. 2018;22:235\u2013248. doi: 10.4196/kjpp.2018.22.3.235.", "ArticleIdList": ["10.4196/kjpp.2018.22.3.235", "PMC5928337", "29719446"]}, {"Citation": "Salvador J.A.R., Leal A.S., Valdeira A.S., Gon\u00e7alves B.M.F., Alho D.P.S., Figueiredo S.A.C., Silvestre S.M., Mendes V.I.S. Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment. Eur. J. Med. Chem. 2017;142:95\u2013130. doi: 10.1016/j.ejmech.2017.07.013.", "ArticleIdList": ["10.1016/j.ejmech.2017.07.013", "28754470"]}, {"Citation": "Guti\u00e9rrez-Rebolledo G.A., Siordia-Reyes A.G., Meckes-Fischer M., Jim\u00e9nez-Arellanes A. Hepatoprotective properties of oleanolic and ursolic acids in antitubercular drug-induced liver damage. Asian Pac. J. Trop. Med. 2016;9:644\u2013651. doi: 10.1016/j.apjtm.2016.05.015.", "ArticleIdList": ["10.1016/j.apjtm.2016.05.015", "27393091"]}, {"Citation": "Ayeleso T.B., Matumba M.G., Mukwevho E. Oleanolic Acid and Its Derivatives: Biological Activities and Therapeutic Potential in Chronic Diseases. Molecules. 2017;22:1915. doi: 10.3390/molecules22111915.", "ArticleIdList": ["10.3390/molecules22111915", "PMC6150249", "29137205"]}, {"Citation": "Tsai S.J., Yin M.C. Antioxidative and anti-inflammatory protection of oleanolic acid and ursolic acid in PC12 cells. J. Food Sci. 2008;73:H174\u2013H178. doi: 10.1111/j.1750-3841.2008.00864.x.", "ArticleIdList": ["10.1111/j.1750-3841.2008.00864.x", "18803714"]}, {"Citation": "Laszczyk M.N. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 2009;75:1549\u20131560. doi: 10.1055/s-0029-1186102.", "ArticleIdList": ["10.1055/s-0029-1186102", "19742422"]}, {"Citation": "Radwan M.O., Abd-Alla H.I., Alsaggaf A.T., El-Mezayen H., Abourehab M.A.S., El-Beeh M.E., Tateishi H., Otsuka M., Fujita M. Gypsogenin Battling for a Front Position in the Pentacyclic Triterpenes Game of Thrones on Anti-Cancer Therapy: A Critical Review\u2014Dedicated to the Memory of Professor Hanaa M. Rady. Molecules. 2023;28:5677. doi: 10.3390/molecules28155677.", "ArticleIdList": ["10.3390/molecules28155677", "PMC10420691", "37570648"]}, {"Citation": "Radwan M.O., Ismail M.A.H., El-Mekkawy S., Ismail N.S.M., Hanna A.G. Synthesis and biological activity of new 18\u03b2-glycyrrhetinic acid derivatives. Arab. J. Chem. 2016;9:390\u2013399. doi: 10.1016/j.arabjc.2013.06.032.", "ArticleIdList": ["10.1016/j.arabjc.2013.06.032"]}, {"Citation": "Gudoityte E., Arandarcikaite O., Mazeikiene I., Bendokas V., Liobikas J. Ursolic and Oleanolic Acids: Plant Metabolites with Neuroprotective Potential. Int. J. Mol. Sci. 2021;22:4599. doi: 10.3390/ijms22094599.", "ArticleIdList": ["10.3390/ijms22094599", "PMC8124962", "33925641"]}, {"Citation": "Jin L., Martynowski D., Zheng S., Wada T., Xie W., Li Y. Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma. Mol. Endocrinol. 2010;24:923\u2013929. doi: 10.1210/me.2009-0507.", "ArticleIdList": ["10.1210/me.2009-0507", "PMC2870936", "20203100"]}, {"Citation": "Guo F., Gao Y., Li X., Lei X. Natural Product 2-Oxokolavenol Is a Novel FXR Agonist. Molecules. 2022;27:8968. doi: 10.3390/molecules27248968.", "ArticleIdList": ["10.3390/molecules27248968", "PMC9786051", "36558100"]}, {"Citation": "Yamada T., Sugimoto K. Guggulsterone and Its Role in Chronic Diseases. Adv. Exp. Med. Biol. 2016;929:329\u2013361. doi: 10.1007/978-3-319-41342-6_15.", "ArticleIdList": ["10.1007/978-3-319-41342-6_15", "27771932"]}, {"Citation": "Jin L., Feng X., Rong H., Pan Z., Inaba Y., Qiu L., Zheng W., Lin S., Wang R., Wang Z., et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat. Commun. 2013;4:1937. doi: 10.1038/ncomms2924.", "ArticleIdList": ["10.1038/ncomms2924", "23728580"]}, {"Citation": "Grienke U., Mih\u00e1ly-Bison J., Schuster D., Afonyushkin T., Binder M., Guan S.-H., Cheng C.-R., Wolber G., Stuppner H., Guo D.-A., et al. Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum. Bioorg. Med. Chem. 2011;19:6779\u20136791. doi: 10.1016/j.bmc.2011.09.039.", "ArticleIdList": ["10.1016/j.bmc.2011.09.039", "PMC3254236", "22014750"]}, {"Citation": "Shishodia S., Azu N., Rosenzweig J.A., Jackson D.A. Guggulsterone for Chemoprevention of Cancer. Curr. Pharm. Des. 2016;22:294\u2013306. doi: 10.2174/1381612822666151112153117.", "ArticleIdList": ["10.2174/1381612822666151112153117", "26561056"]}, {"Citation": "Jayasuriya H., Herath K.B., Ondeyka J.G., Guan Z., Borris R.P., Tiwari S., de Jong W., Chavez F., Moss J., Stevenson D.W., et al. Diterpenoid, steroid, and triterpenoid agonists of liver X receptors from diversified terrestrial plants and marine sources. J. Nat. Prod. 2005;68:1247\u20131252. doi: 10.1021/np050182g.", "ArticleIdList": ["10.1021/np050182g", "16124770"]}, {"Citation": "Renga B., Mencarelli A., D\u2019Amore C., Cipriani S., D\u2019Auria M.V., Sepe V., Chini M.G., Monti M.C., Bifulco G., Zampella A., et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS ONE. 2012;7:e30443. doi: 10.1371/journal.pone.0030443.", "ArticleIdList": ["10.1371/journal.pone.0030443", "PMC3264597", "22291955"]}, {"Citation": "Gu M., Zhao P., Zhang S., Fan S., Yang L., Tong Q., Ji G., Huang C. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice. Br. J. Pharmacol. 2019;176:847\u2013863. doi: 10.1111/bph.14570.", "ArticleIdList": ["10.1111/bph.14570", "PMC6433649", "30635917"]}, {"Citation": "Hu M., Luo Q., Alitongbieke G., Chong S., Xu C., Xie L., Chen X., Zhang D., Zhou Y., Wang Z., et al. Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy. Mol. Cell. 2017;66:141\u2013153.e6. doi: 10.1016/j.molcel.2017.03.008.", "ArticleIdList": ["10.1016/j.molcel.2017.03.008", "PMC5761061", "28388439"]}, {"Citation": "Liu L., Ma D., Zhuo L., Pang X., You J., Feng J. Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders. Curr. Neuropharmacol. 2021;19:486\u2013497. doi: 10.2174/1570159X18666200606231723.", "ArticleIdList": ["10.2174/1570159X18666200606231723", "PMC8206462", "32504502"]}, {"Citation": "Liu J., Liu J., Meng C., Gu Q., Huang C., Liu F., Xia C. NRF2 and FXR dual signaling pathways cooperatively regulate the effects of oleanolic acid on cholestatic liver injury. Phytomedicine. 2023;108:154529. doi: 10.1016/j.phymed.2022.154529.", "ArticleIdList": ["10.1016/j.phymed.2022.154529", "36343550"]}, {"Citation": "Liu J., Liu J., Meng C., Huang C., Liu F., Xia C. Oleanolic acid alleviates ANIT-induced cholestatic liver injury by activating Fxr and Nrf2 pathways to ameliorate disordered bile acids homeostasis. Phytomedicine. 2022;102:154173. doi: 10.1016/j.phymed.2022.154173.", "ArticleIdList": ["10.1016/j.phymed.2022.154173", "35605478"]}, {"Citation": "Ma H., Bao Y., Niu S., Wang S., Li Y., He H., Zhang N., Fang W. Structure Optimization of 12\u03b2-O-\u03b3-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy. Pharmaceuticals. 2023;16:758. doi: 10.3390/ph16050758.", "ArticleIdList": ["10.3390/ph16050758", "PMC10221314", "37242541"]}, {"Citation": "Wang Y., Porter W.W., Suh N., Honda T., Gribble G.W., Leesnitzer L.M., Plunket K.D., Mangelsdorf D.J., Blanchard S.G., Willson T.M., et al. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol. Endocrinol. 2000;14:1550\u20131556. doi: 10.1210/mend.14.10.0545.", "ArticleIdList": ["10.1210/mend.14.10.0545", "11043571"]}, {"Citation": "Christensen K.B., J\u00f8rgensen M., Kotowska D., Petersen R.K., Kristiansen K., Christensen L.P. Activation of the nuclear receptor PPAR\u03b3 by metabolites isolated from sage (Salvia officinalis L.) J. Ethnopharmacol. 2010;132:127\u2013133. doi: 10.1016/j.jep.2010.07.054.", "ArticleIdList": ["10.1016/j.jep.2010.07.054", "20696231"]}, {"Citation": "Pan Y., Zhou F., Song Z., Huang H., Chen Y., Shen Y., Jia Y., Chen J. Oleanolic acid protects against pathogenesis of atherosclerosis, possibly via FXR-mediated angiotensin (Ang)-(1\u20137) upregulation. Biomed. Pharmacother. 2018;97:1694\u20131700. doi: 10.1016/j.biopha.2017.11.151.", "ArticleIdList": ["10.1016/j.biopha.2017.11.151", "29793333"]}, {"Citation": "Radwan M.O., Kadasah S.F., Aljubiri S.M., Alrefaei A.F., El-Maghrabey M.H., El Hamd M.A., Tateishi H., Otsuka M., Fujita M. Harnessing Oleanolic Acid and Its Derivatives as Modulators of Metabolic Nuclear Receptors. Biomolecules. 2023;13:1465. doi: 10.3390/biom13101465.", "ArticleIdList": ["10.3390/biom13101465"]}, {"Citation": "Lu Y., Zheng W., Lin S., Guo F., Zhu Y., Wei Y., Liu X., Jin S., Jin L., Li Y. Identification of an Oleanane-Type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity. Mol. Pharmacol. 2018;93:63\u201372. doi: 10.1124/mol.117.109900.", "ArticleIdList": ["10.1124/mol.117.109900", "29162643"]}, {"Citation": "Fallon C.M., Smyth J.S., Quach A., Lajczak-McGinley N., O\u2019toole A., Barrett K.E., Sheridan H., Keely S.J. Pentacyclic triterpenes modulate farnesoid X receptor expression in colonic epithelial cells: Implications for colonic secretory function. J. Biol. Chem. 2022;298:102569. doi: 10.1016/j.jbc.2022.102569.", "ArticleIdList": ["10.1016/j.jbc.2022.102569", "PMC9663526", "36209824"]}, {"Citation": "Modica S., Murzilli S., Salvatore L., Schmidt D.R., Moschetta A. Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis. Cancer Res. 2008;68:9589\u20139594. doi: 10.1158/0008-5472.CAN-08-1791.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-1791", "19047134"]}, {"Citation": "Lee A.-W., Chen T.-L., Shih C.-M., Huang C.-Y., Tsao N.-W., Chang N.-C., Chen Y.-H., Fong T.-H., Lin F.-Y. Ursolic Acid Induces Allograft Inflammatory Factor-1 Expression via a Nitric Oxide-Related Mechanism and Increases Neovascularization. J. Agric. Food Chem. 2010;58:12941\u201312949. doi: 10.1021/jf103265x.", "ArticleIdList": ["10.1021/jf103265x", "21070071"]}, {"Citation": "Zhang F., Daimaru E., Ohnishi M., Kinoshita M., Tokuji Y. Oleanolic Acid and Ursolic Acid in Commercial Dried Fruits. Food Sci. Technol. Res. 2013;19:113\u2013116. doi: 10.3136/fstr.19.113.", "ArticleIdList": ["10.3136/fstr.19.113"]}, {"Citation": "Habtemariam S. Antioxidant and Anti-inflammatory Mechanisms of Neuroprotection by Ursolic Acid: Addressing Brain Injury, Cerebral Ischemia, Cognition Deficit, Anxiety, and Depression. Oxid. Med. Cell. Longev. 2019;2019:8512048. doi: 10.1155/2019/8512048.", "ArticleIdList": ["10.1155/2019/8512048", "PMC6541953", "31223427"]}, {"Citation": "Hussain H., Green I.R., Ali I., Khan I.A., Ali Z., Al-Sadi A.M., Ahmed I. Ursolic acid derivatives for pharmaceutical use: A patent review (2012\u20132016) Expert Opin. Ther. Pat. 2017;27:1061\u20131072. doi: 10.1080/13543776.2017.1344219.", "ArticleIdList": ["10.1080/13543776.2017.1344219", "28637397"]}, {"Citation": "Yan S., Huang C., Wu S., Yin M. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol. In Vitro. 2010;24:842\u2013848. doi: 10.1016/j.tiv.2009.12.008.", "ArticleIdList": ["10.1016/j.tiv.2009.12.008", "20005942"]}, {"Citation": "Son H.-S., Kwon H.Y., Sohn E.J., Lee J.-H., Woo H.-J., Yun M., Kim S.-H., Kim Y.-C. Activation of AMP-activated protein kinase and phosphorylation of glycogen synthase kinase3 \u03b2 mediate ursolic acid induced apoptosis in HepG2 liver cancer cells. Phytother. Res. 2013;27:1714\u20131722. doi: 10.1002/ptr.4925.", "ArticleIdList": ["10.1002/ptr.4925", "23325562"]}, {"Citation": "Castrej\u00f3n-Jim\u00e9nez N.S., Leyva-Paredes K., Baltierra-Uribe S.L., Castillo-Cruz J., Campillo-Navarro M., Hern\u00e1ndez-P\u00e9rez A.D., Luna-Angulo A.B., Chac\u00f3n-Salinas R., Coral-V\u00e1zquez R.M., Estrada-Garc\u00eda I., et al. Ursolic and Oleanolic Acids Induce Mitophagy in A549 Human Lung Cancer Cells. Molecules. 2019;24:3444. doi: 10.3390/molecules24193444.", "ArticleIdList": ["10.3390/molecules24193444", "PMC6803966", "31547522"]}, {"Citation": "Kornel A., Nadile M., Tsiani E. Evidence of the Beneficial Effects of Ursolic Acid against Lung Cancer. Molecules. 2022;27:7466. doi: 10.3390/molecules27217466.", "ArticleIdList": ["10.3390/molecules27217466", "PMC9655894", "36364289"]}, {"Citation": "Gao N., Cheng S., Budhraja A., Gao Z., Chen J., Liu E.-H., Huang C., Chen D., Yang Z., Liu Q., et al. Ursolic acid induces apoptosis in human leukaemia cells and exhibits anti-leukaemic activity in nude mice through the PKB pathway. Br. J. Pharmacol. 2012;165:1813\u20131826. doi: 10.1111/j.1476-5381.2011.01684.x.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01684.x", "PMC3372832", "21950524"]}, {"Citation": "Wu B., Wang X., Chi Z.-F., Hu R., Zhang R., Yang W., Liu Z.-G. Ursolic acid-induced apoptosis in K562 cells involving upregulation of PTEN gene expression and inactivation of the PI3K/Akt pathway. Arch. Pharm. Res. 2012;35:543\u2013548. doi: 10.1007/s12272-012-0318-1.", "ArticleIdList": ["10.1007/s12272-012-0318-1", "22477202"]}, {"Citation": "Ciftci H.I., Radwan M.O., Ozturk S.E., Ulusoy N.G., Sozer E., Ellakwa D.E., Ocak Z., Can M., Ali T.F., Abd-Alla H.I., et al. Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity. Molecules. 2019;24:3535. doi: 10.3390/molecules24193535.", "ArticleIdList": ["10.3390/molecules24193535", "PMC6804044", "31574910"]}, {"Citation": "Wang S., Chang X., Zhang J., Li J., Wang N., Yang B., Pan B., Zheng Y., Wang X., Ou H., et al. Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling. Front. Oncol. 2021;11:745584. doi: 10.3389/fonc.2021.745584.", "ArticleIdList": ["10.3389/fonc.2021.745584", "PMC8457520", "34568078"]}, {"Citation": "Luo J., Hu Y.-L., Wang H. Ursolic acid inhibits breast cancer growth by inhibiting proliferation, inducing autophagy and apoptosis, and suppressing inflammatory responses via the PI3K/AKT and NF-\u03baB signaling pathways in vitro. Exp. Ther. Med. 2017;14:3623\u20133631. doi: 10.3892/etm.2017.4965.", "ArticleIdList": ["10.3892/etm.2017.4965", "PMC5639319", "29042957"]}, {"Citation": "Mu D., Zhou G., Li J., Su B., Guo H. Ursolic acid activates the apoptosis of prostate cancer via ROCK/PTEN mediated mitochondrial translocation of cofilin-1. Oncol. Lett. 2018;15:3202\u20133206. doi: 10.3892/ol.2017.7689.", "ArticleIdList": ["10.3892/ol.2017.7689", "PMC5778871", "29435058"]}, {"Citation": "Kornel A., Nadile M., Retsidou M.I., Sakellakis M., Gioti K., Beloukas A., Sze N.S.K., Klentrou P., Tsiani E. Ursolic Acid against Prostate and Urogenital Cancers: A Review of In Vitro and In Vivo Studies. Int. J. Mol. Sci. 2023;24:7414. doi: 10.3390/ijms24087414.", "ArticleIdList": ["10.3390/ijms24087414", "PMC10138876", "37108576"]}, {"Citation": "Xu H., Zhou Z., Dong J., Lei M. Suppression of cervical cancer cell survival by ursolic acid extracted from Catalpa bungei leaves. Pharmacogn. Mag. 2018;14:425\u2013431. doi: 10.4103/pm.pm_408_17.", "ArticleIdList": ["10.4103/pm.pm_408_17"]}, {"Citation": "Wang S., Meng X., Dong Y. Ursolic acid nanoparticles inhibit cervical cancer growth in vitro and in vivo via apoptosis induction. Int. J. Oncol. 2017;50:1330\u20131340. doi: 10.3892/ijo.2017.3890.", "ArticleIdList": ["10.3892/ijo.2017.3890", "28259944"]}, {"Citation": "Mancha-Ramirez A.M., Slaga T.J. Ursolic Acid and Chronic Disease: An Overview of UA\u2019s Effects On Prevention and Treatment of Obesity and Cancer. Adv. Exp. Med. Biol. 2016;928:75\u201396. doi: 10.1007/978-3-319-41334-1_4.", "ArticleIdList": ["10.1007/978-3-319-41334-1_4", "27671813"]}, {"Citation": "Tian C., Li J., Bao Y., Gao L., Song L., Li K., Sun M. Ursolic acid ameliorates obesity of mice fed with high-fat diet via alteration of gut microbiota and amino acid metabolism.  [(accessed on 4 October 2023)];Front. Microbiol. 2023 14:1183598.  doi: 10.3389/fmicb.2023.1183598. Available online:  https://www.frontiersin.org/articles/10.3389/fmicb.2023.1183598.", "ArticleIdList": ["10.3389/fmicb.2023.1183598", "10.3389/fmicb.2023.1183598", "PMC10359042", "37485499"]}, {"Citation": "Rao V.S., de Melo C.L., Queiroz M.G.R., Lemos T.L., Menezes D.B., Melo T.S., Santos F.A., Silva F.S.G., Oliveira P.J., Duarte M.F., et al. Ursolic acid, a pentacyclic triterpene from Sambucus australis, prevents abdominal adiposity in mice fed a high-fat diet. J. Med. Food. 2011;14:1375\u20131382. doi: 10.1089/jmf.2010.0267.", "ArticleIdList": ["10.1089/jmf.2010.0267", "21612453"]}, {"Citation": "Kim J., Jang D.S., Kim H., Kim J.S. Anti-lipase and lipolytic activities of ursolic acid isolated from the roots of Actinidia arguta. Arch. Pharm. Res. 2009;32:983\u2013987. doi: 10.1007/s12272-009-1702-3.", "ArticleIdList": ["10.1007/s12272-009-1702-3", "19641878"]}, {"Citation": "Kunkel S.D., Elmore C.J., Bongers K.S., Ebert S.M., Fox D.K., Dyle M.C., Bullard S.A., Adams C.M. Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS ONE. 2012;7:e39332. doi: 10.1371/journal.pone.0039332.", "ArticleIdList": ["10.1371/journal.pone.0039332", "PMC3379974", "22745735"]}, {"Citation": "Katashima C.K., Silva V.R., Gomes T.L., Pichard C., Pimentel G.D. Ursolic acid and mechanisms of actions on adipose and muscle tissue: A systematic review. Obes. Rev. 2017;18:700\u2013711. doi: 10.1111/obr.12523.", "ArticleIdList": ["10.1111/obr.12523", "28335087"]}, {"Citation": "Jung S.H., Ha Y.J., Shim E.K., Choi S.Y., Jin J.L., Yun-Choi H.S., Lee J.R. Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activator. Biochem. J. 2007;403:243\u2013250. doi: 10.1042/BJ20061123.", "ArticleIdList": ["10.1042/BJ20061123", "PMC1874232", "17201692"]}, {"Citation": "Silva F.S.G., Oliveira P.J., Duarte M.F. Oleanolic, Ursolic, and Betulinic Acids as Food Supplements or Pharmaceutical Agents for Type 2 Diabetes: Promise or Illusion? J. Agric. Food Chem. 2016;64:2991\u20133008. doi: 10.1021/acs.jafc.5b06021.", "ArticleIdList": ["10.1021/acs.jafc.5b06021", "27012451"]}, {"Citation": "Azevedo M.F., Camsari C., S\u00e1 C.M., Lima C.F., Fernandes-Ferreira M., Pereira-Wilson C. Ursolic acid and luteolin-7-glucoside improve lipid profiles and increase liver glycogen content through glycogen synthase kinase-3. Phytother. Res. 2010;24((Suppl. 2)):S220\u2013S224. doi: 10.1002/ptr.3118.", "ArticleIdList": ["10.1002/ptr.3118", "20127879"]}, {"Citation": "Pozo M., Castilla V., Gutierrez C., de Nicol\u00e1s R., Egido J., Gonz\u00e1lez-Cabrero J. Ursolic acid inhibits neointima formation in the rat carotid artery injury model. Atherosclerosis. 2006;184:53\u201362. doi: 10.1016/j.atherosclerosis.2005.04.014.", "ArticleIdList": ["10.1016/j.atherosclerosis.2005.04.014", "15922347"]}, {"Citation": "Kashyap D., Sharma A., Tuli H.S., Punia S., Sharma A.K. Ursolic Acid and Oleanolic Acid: Pentacyclic Terpenoids with Promising Anti-Inflammatory Activities. Recent Pat. Inflamm. Allergy Drug Discov. 2016;10:21\u201333. doi: 10.2174/1872213X10666160711143904.", "ArticleIdList": ["10.2174/1872213X10666160711143904", "27531153"]}, {"Citation": "Bakhtiari N., Moslemee-Jalalvand E., Kazemi J. Ursolic acid: A versatile triterpenoid compound in regulating the aging. Physiol. Pharmacol. 2017;21:15\u201324."}, {"Citation": "Ciftci H.I., Ozturk S.E., Ali T.F.S., Radwan M.O., Tateishi H., Koga R., Ocak Z., Can M., Otsuka M., Fujita M. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities. Biol. Pharm. Bull. 2018;41:570\u2013574. doi: 10.1248/bpb.b17-00902.", "ArticleIdList": ["10.1248/bpb.b17-00902", "29386476"]}, {"Citation": "Ciftci H.I., Radwan M.O., Sever B., Hamdy A.K., Emirda\u011f S., Ulusoy N.G., Sozer E., Can M., Yayli N., Araki N., et al. EGFR-Targeted Pentacyclic Triterpene Analogues for Glioma Therapy. Int. J. Mol. Sci. 2021;22:10945. doi: 10.3390/ijms222010945.", "ArticleIdList": ["10.3390/ijms222010945", "PMC8537327", "34681605"]}, {"Citation": "Nguyen H.N., Ullevig S.L., Short J.D., Wang L., Ahn Y.J., Asmis R. Ursolic Acid and Related Analogues: Triterpenoids with Broad Health Benefits. Antioxidants. 2021;10:1161. doi: 10.3390/antiox10081161.", "ArticleIdList": ["10.3390/antiox10081161", "PMC8388988", "34439409"]}, {"Citation": "Berger J., Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002;53:409\u2013435. doi: 10.1146/annurev.med.53.082901.104018.", "ArticleIdList": ["10.1146/annurev.med.53.082901.104018", "11818483"]}, {"Citation": "Zhang F., Lavan B.E., Gregoire F.M. Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res. 2007;2007:32696. doi: 10.1155/2007/32696.", "ArticleIdList": ["10.1155/2007/32696", "PMC1783742", "17389769"]}, {"Citation": "Allen T., Zhang F., Moodie S.A., Clemens L.E., Smith A., Gregoire F., Bell A., Muscat G.E., Gustafson T.A. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes. 2006;55:2523\u20132533. doi: 10.2337/db06-0618.", "ArticleIdList": ["10.2337/db06-0618", "16936200"]}, {"Citation": "Zheng W., Feng X., Qiu L., Pan Z., Wang R., Lin S., Hou D., Jin L., Li Y. Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes. Diabetologia. 2013;56:401\u2013411. doi: 10.1007/s00125-012-2777-9.", "ArticleIdList": ["10.1007/s00125-012-2777-9", "23178929"]}, {"Citation": "Thuillier P., Anchiraico G.J., Nickel K.P., Maldve R.E., Gimenez-Conti I., Muga S.J., Liu K.-L., Fischer S.M., Belury M.A. Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol. Carcinog. 2000;29:134\u2013142. doi: 10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F.", "ArticleIdList": ["10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F", "11108658"]}, {"Citation": "Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA. 1999;96:7473\u20137478. doi: 10.1073/pnas.96.13.7473.", "ArticleIdList": ["10.1073/pnas.96.13.7473", "PMC22110", "10377439"]}, {"Citation": "Sanderson L.M., Degenhardt T., Koppen A., Kalkhoven E., Desvergne B., M\u00fcller M., Kersten S. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol. Cell. Biol. 2009;29:6257\u20136267. doi: 10.1128/MCB.00370-09.", "ArticleIdList": ["10.1128/MCB.00370-09", "PMC2786701", "19805517"]}, {"Citation": "Hou G., Yin Y., Han D., Wang Q.-Y., Kang J. Rosiglitazone attenuates the metalloprotease/anti-metalloprotease imbalance in emphysema induced by cigarette smoke: Involvement of extracellular signal-regulated kinase and NF\u03baB signaling. Int. J. Chron Obs. Pulmon Dis. 2015;10:715\u2013724. doi: 10.2147/COPD.S77514.", "ArticleIdList": ["10.2147/COPD.S77514", "PMC4396520", "25897215"]}, {"Citation": "Fajas L., Auboeuf D., Rasp\u00e9 E., Schoonjans K., Lefebvre A.-M., Saladin R., Najib J., Laville M., Fruchart J.-C., Deeb S., et al. The Organization, Promoter Analysis, and Expression of the Human PPAR\u03b3 Gene*. J. Biol. Chem. 1997;272:18779\u201318789. doi: 10.1074/jbc.272.30.18779.", "ArticleIdList": ["10.1074/jbc.272.30.18779", "9228052"]}, {"Citation": "Orasanu G., Ziouzenkova O., Devchand P.R., Nehra V., Hamdy O., Horton E.S., Plutzky J. The PPAR\u03b3 Agonist Pioglitazone Represses Inflammation In A PPAR\u03b1-Dependent Manner In Vitro and In Vivo In Mice. J. Am. Coll. Cardiol. 2008;52:869\u2013881. doi: 10.1016/j.jacc.2008.04.055.", "ArticleIdList": ["10.1016/j.jacc.2008.04.055", "PMC2633943", "18755353"]}, {"Citation": "Enayati A., Ghojoghnejad M., Roufogalis B.D., Maollem S.A., Sahebkar A. Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments. PPAR Res. 2022;2022:4714914. doi: 10.1155/2022/4714914.", "ArticleIdList": ["10.1155/2022/4714914", "PMC9453090", "36092543"]}, {"Citation": "Lee H.K., Nam G.W., Kim S.H., Lee S.H. Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-\u03b1 pathway. Exp. Dermatol. 2006;15:66\u201373. doi: 10.1111/j.0906-6705.2005.00386.x.", "ArticleIdList": ["10.1111/j.0906-6705.2005.00386.x", "16364033"]}, {"Citation": "Lim S.W., Hong S.P., Jeong S.W., Kim B., Bak H., Ryoo H.C., Lee S.H., Ahn S.K. Simultaneous effect of ursolic acid and oleanolic acid on epidermal permeability barrier function and epidermal keratinocyte differentiation via peroxisome proliferator-activated receptor-\u03b1. J. Dermatol. 2007;34:625\u2013634. doi: 10.1111/j.1346-8138.2007.00344.x.", "ArticleIdList": ["10.1111/j.1346-8138.2007.00344.x", "17727365"]}, {"Citation": "Junco J.J., Cho J., Mancha A., Malik G., Wei S.-J., Kim D.J., Liang H., DiGiovanni J., Slaga T.J. Role of AMPK and PPAR\u03b1 in the anti-skin cancer effects of ursolic acid. Mol. Carcinog. 2018;57:1698\u20131706. doi: 10.1002/mc.22890.", "ArticleIdList": ["10.1002/mc.22890", "PMC6519015", "30129681"]}, {"Citation": "Jia Y., Bhuiyan M.J.H., Jun H.-J., Lee J.H., Hoang M.H., Lee H.-J., Kim N., Lee D., Hwang K.Y., Hwang B.Y., et al. Ursolic acid is a PPAR-\u03b1 agonist that regulates hepatic lipid metabolism. Bioorg. Med. Chem. Lett. 2011;21:5876\u20135880. doi: 10.1016/j.bmcl.2011.07.095.", "ArticleIdList": ["10.1016/j.bmcl.2011.07.095", "21855333"]}, {"Citation": "Kimura S., Noda T., Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452\u2013460. doi: 10.4161/auto.4451.", "ArticleIdList": ["10.4161/auto.4451", "17534139"]}, {"Citation": "Jia Y., Kim S., Kim J., Kim B., Wu C., Lee J.H., Jun H.-J., Kim N., Lee D., Lee S.-J. Ursolic acid improves lipid and glucose metabolism in high-fat-fed C57BL/6J mice by activating peroxisome proliferator-activated receptor alpha and hepatic autophagy. Mol. Nutr. Food Res. 2015;59:344\u2013354. doi: 10.1002/mnfr.201400399.", "ArticleIdList": ["10.1002/mnfr.201400399", "25418615"]}, {"Citation": "Wang Y.L., Wang Z.J., Shen H.L., Yin M., Tang K.X. Effects of artesunate and ursolic acid on hyperlipidemia and its complications in rabbit. Eur. J. Pharm. Sci. 2013;50:366\u2013371. doi: 10.1016/j.ejps.2013.08.003.", "ArticleIdList": ["10.1016/j.ejps.2013.08.003", "23954455"]}, {"Citation": "Li S., Meng F., Liao X., Wang Y., Sun Z., Guo F., Li X., Meng M., Li Y., Sun C. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS ONE. 2014;9:e86724. doi: 10.1371/journal.pone.0086724.", "ArticleIdList": ["10.1371/journal.pone.0086724", "PMC3906058", "24489777"]}, {"Citation": "Zhang Y., Song C., Li H., Hou J., Li D. Ursolic acid prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPAR\u03b1. Mol. Med. Rep. 2016;13:5309\u20135316. doi: 10.3892/mmr.2016.5172.", "ArticleIdList": ["10.3892/mmr.2016.5172", "27108888"]}, {"Citation": "Xu Y., Gu Q., Liu N., Yan Y., Yang X., Hao Y., Qu C. PPAR\u03b3 Alleviates Right Ventricular Failure Secondary to Pulmonary Arterial Hypertension in Rats. Int. Heart J. 2017;58:948\u2013956. doi: 10.1536/ihj.16-591.", "ArticleIdList": ["10.1536/ihj.16-591", "29151490"]}, {"Citation": "Gao X., Zhang Z., Li X.B., Wei Q., Li H., Li C., Chen H., Liu C., He K. Ursolic Acid Improves Monocrotaline-Induced Right Ventricular Remodeling by Regulating Metabolism. J. Cardiovasc. Pharmacol. 2020;75:545\u2013555. doi: 10.1097/FJC.0000000000000815.", "ArticleIdList": ["10.1097/FJC.0000000000000815", "32141989"]}, {"Citation": "Hirasawa H., Chiba T., Ueki S., Kamada Y., Ito W., Takeda M., Fujita M., Kato H., Kayaba H., Chihara J. The synthetic PPARgamma agonist troglitazone inhibits eotaxin-enhanced eosinophil adhesion to ICAM-1-coated plates. Int. Arch. Allergy Immunol. 2008;146((Suppl. 1)):11\u201315. doi: 10.1159/000126054.", "ArticleIdList": ["10.1159/000126054", "18504400"]}, {"Citation": "Kim S.-H., Hong J.-H., Lee Y.-C. Ursolic acid, a potential PPAR\u03b3 agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, and IL-17 in a mouse model of allergic asthma. Eur. J. Pharmacol. 2013;701:131\u2013143. doi: 10.1016/j.ejphar.2012.11.033.", "ArticleIdList": ["10.1016/j.ejphar.2012.11.033", "23201068"]}, {"Citation": "Wang Y., He Z., Deng S. Ursolic acid reduces the metalloprotease/anti-metalloprotease imbalance in cerebral ischemia and reperfusion injury. Drug Des. Devel. Ther. 2016;10:1663\u20131674. doi: 10.2147/DDDT.S103829.", "ArticleIdList": ["10.2147/DDDT.S103829", "PMC4876798", "27274199"]}, {"Citation": "Wang Y., Qiu L., Deng S., Liu F., He Z., Li M., Wang Y. Ursolic acid promotes microglial polarization toward the M2 phenotype via PPAR\u03b3 regulation of MMP2 transcription. Neurotoxicology. 2023;96:81\u201391. doi: 10.1016/j.neuro.2023.04.001.", "ArticleIdList": ["10.1016/j.neuro.2023.04.001", "37019307"]}, {"Citation": "Zhang Y., Li X., Ciric B., Curtis M.T., Chen W.-J., Rostami A., Zhang G.-X. A dual effect of ursolic acid to the treatment of multiple sclerosis through both immunomodulation and direct remyelination. Proc. Natl. Acad. Sci. USA. 2020;117:9082\u20139093. doi: 10.1073/pnas.2000208117.", "ArticleIdList": ["10.1073/pnas.2000208117", "PMC7183235", "32253301"]}, {"Citation": "Fan S., Zhang Y., Hu N., Sun Q., Ding X., Li G., Zheng B., Gu M., Huang F., Sun Y.-Q., et al. Extract of Kuding tea prevents high-fat diet-induced metabolic disorders in C57BL/6 mice via liver X receptor (LXR) \u03b2 antagonism. PLoS ONE. 2012;7:e51007. doi: 10.1371/journal.pone.0051007.", "ArticleIdList": ["10.1371/journal.pone.0051007", "PMC3514219", "23226556"]}, {"Citation": "Lin Y.-N., Wang C.C.N., Chang H.-Y., Chu F.-Y., Hsu Y.-A., Cheng W.-K., Ma W.-C., Chen C.-J., Wan L., Lim Y.-P. Ursolic Acid, a Novel Liver X Receptor \u03b1 (LXR\u03b1) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis. J. Agric. Food Chem. 2018;66:11647\u201311662. doi: 10.1021/acs.jafc.8b04116.", "ArticleIdList": ["10.1021/acs.jafc.8b04116", "30359008"]}, {"Citation": "Chang H.-Y., Chen C.-J., Ma W.-C., Cheng W.-K., Lin Y.-N., Lee Y.-R., Chen J.-J., Lim Y.-P. Modulation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation by ursolic acid (UA) attenuates rifampin-isoniazid cytotoxicity. Phytomedicine. 2017;36:37\u201349. doi: 10.1016/j.phymed.2017.09.016.", "ArticleIdList": ["10.1016/j.phymed.2017.09.016", "29157826"]}, {"Citation": "Xu T., Wang X., Zhong B., Nurieva R.I., Ding S., Dong C. Ursolic Acid Suppresses Interleukin-17 (IL-17) Production by Selectively Antagonizing the Function of ROR\u03b3t Protein*. J. Biol. Chem. 2011;286:22707\u201322710. doi: 10.1074/jbc.C111.250407.", "ArticleIdList": ["10.1074/jbc.C111.250407", "PMC3123037", "21566134"]}, {"Citation": "Baek S.-Y., Lee J., Lee D.-G., Park M.-K., Lee J., Kwok S.-K., Cho M.-L., Park S.-H. Ursolic acid ameliorates autoimmune arthritis via suppression of Th17 and B cell differentiation. Acta Pharmacol. Sin. 2014;35:1177\u20131187. doi: 10.1038/aps.2014.58.", "ArticleIdList": ["10.1038/aps.2014.58", "PMC4155530", "25087995"]}, {"Citation": "Zou H., Yang Y., Chen H.-W. Natural compounds ursolic acid and digoxin exhibit inhibitory activities to cancer cells in ROR\u03b3-dependent and -independent manner. Front. Pharmacol. 2023;14:1146741. doi: 10.3389/fphar.2023.1146741.", "ArticleIdList": ["10.3389/fphar.2023.1146741", "PMC10169565", "37180705"]}, {"Citation": "Dixon E.D., Nardo A.D., Claudel T., Trauner M. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes. 2021;12:645. doi: 10.3390/genes12050645.", "ArticleIdList": ["10.3390/genes12050645", "PMC8145571", "33926085"]}, {"Citation": "Lin Z., Zhang Y., Zhang Y., Shen H., Hu L., Jiang H., Shen X. Oleanolic acid derivative NPLC441 potently stimulates glucose transport in 3T3-L1 adipocytes via a multi-target mechanism. Biochem. Pharmacol. 2008;76:1251\u20131262. doi: 10.1016/j.bcp.2008.08.016.", "ArticleIdList": ["10.1016/j.bcp.2008.08.016", "18778688"]}, {"Citation": "Edwards P.A., Kennedy M.A., Mak P.A. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vasc. Pharmacol. 2002;38:249\u2013256. doi: 10.1016/S1537-1891(02)00175-1.", "ArticleIdList": ["10.1016/S1537-1891(02)00175-1", "12449021"]}, {"Citation": "Higuchi N., Kato M., Shundo Y., Tajiri H., Tanaka M., Yamashita N., Kohjima M., Kotoh K., Nakamuta M., Takayanagi R., et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 2008;38:1122\u20131129. doi: 10.1111/j.1872-034X.2008.00382.x.", "ArticleIdList": ["10.1111/j.1872-034X.2008.00382.x", "18684130"]}, {"Citation": "Griffett K., Burris T.P. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Front. Med. 2023;10:1102469. doi: 10.3389/fmed.2023.1102469.", "ArticleIdList": ["10.3389/fmed.2023.1102469", "PMC9932051", "36817797"]}, {"Citation": "W\u00fcpper S., L\u00fcersen K., Rimbach G. Chemical Composition, Bioactivity and Safety Aspects of Kuding Tea\u2014From Beverage to Herbal Extract. Nutrients. 2020;12:2796. doi: 10.3390/nu12092796.", "ArticleIdList": ["10.3390/nu12092796", "PMC7551553", "32932672"]}, {"Citation": "Lin Y.-N., Chang H.-Y., Wang C.C.N., Chu F.-Y., Shen H.-Y., Chen C.-J., Lim Y.-P. Oleanolic Acid Inhibits Liver X Receptor Alpha and Pregnane X Receptor to Attenuate Ligand-Induced Lipogenesis. J. Agric. Food Chem. 2018;66:10964\u201310976. doi: 10.1021/acs.jafc.8b03372.", "ArticleIdList": ["10.1021/acs.jafc.8b03372", "30351048"]}, {"Citation": "Svensson S., \u00d6stberg T., Jacobsson M., Norstr\u00f6m C., Stefansson K., Hall\u00e9n D., Johansson I.C., Zachrisson K., Ogg D., Jendeberg L. Crystal structure of the heterodimeric complex of LXR\u03b1 and RXR\u03b2 ligand-binding domains in a fully agonistic conformation. EMBO J. 2003;22:4625\u20134633. doi: 10.1093/emboj/cdg456.", "ArticleIdList": ["10.1093/emboj/cdg456", "PMC212723", "12970175"]}, {"Citation": "Wada T., Gao J., Xie W. PXR and CAR in energy metabolism. Trends Endocrinol. Metab. 2009;20:273\u2013279. doi: 10.1016/j.tem.2009.03.003.", "ArticleIdList": ["10.1016/j.tem.2009.03.003", "19595610"]}, {"Citation": "Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr. Rev. 2002;23:687\u2013702. doi: 10.1210/er.2001-0038.", "ArticleIdList": ["10.1210/er.2001-0038", "12372848"]}, {"Citation": "Ekins S., Chang C., Mani S., Krasowski M.D., Reschly E.J., Iyer M., Kholodovych V., Ai N., Welsh W.J., Sinz M., et al. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol. Pharmacol. 2007;72:592\u2013603. doi: 10.1124/mol.107.038398.", "ArticleIdList": ["10.1124/mol.107.038398", "17576789"]}, {"Citation": "Seow C.L., Lau A.J. Differential activation of pregnane X receptor by carnosic acid, carnosol, ursolic acid, and rosmarinic acid. Pharmacol. Res. 2017;120:23\u201333. doi: 10.1016/j.phrs.2017.03.007.", "ArticleIdList": ["10.1016/j.phrs.2017.03.007", "28288941"]}, {"Citation": "Lin Y.-N., Chen C.-J., Chang H.-Y., Cheng W.-K., Lee Y.-R., Chen J.-J., Lim Y.-P. Oleanolic Acid-Mediated Inhibition of Pregnane X Receptor and Constitutive Androstane Receptor Attenuates Rifampin-Isoniazid Cytotoxicity. J. Agric. Food Chem. 2017;65:8606\u20138616. doi: 10.1021/acs.jafc.7b02696.", "ArticleIdList": ["10.1021/acs.jafc.7b02696", "28945086"]}, {"Citation": "Zhang Z.-H., Tang J.-H., Zhan Z.-L., Zhang X.-L., Wu H.-H., Hou Y.-N. Cellular toxicity of isoniazid together with rifampicin and the metabolites of isoniazid on QSG-7701 hepatocytes. Asian Pac. J. Trop. Med. 2012;5:306\u2013309. doi: 10.1016/S1995-7645(12)60044-3.", "ArticleIdList": ["10.1016/S1995-7645(12)60044-3", "22449523"]}, {"Citation": "Pr\u00e0 M.D., Carta D., Szabadkai G., Suman M., Fri\u00f3n-Herrera Y., Paccagnella N., Castellani G., De Martin S., Ferlin M.G. Targeting RORs nuclear receptors by novel synthetic steroidal inverse agonists for autoimmune disorders. Bioorg. Med. Chem. 2018;26:1686\u20131704. doi: 10.1016/j.bmc.2018.02.018.", "ArticleIdList": ["10.1016/j.bmc.2018.02.018", "29477813"]}, {"Citation": "Pastwi\u0144ska J., Kara\u015b K., Sa\u0142kowska A., Karwaciak I., Cha\u0142a\u015bkiewicz K., Wojtczak B.A., Bachorz R.A., Ratajewski M. Identification of Corosolic and Oleanolic Acids as Molecules Antagonizing the Human ROR\u03b3T Nuclear Receptor Using the Calculated Fingerprints of the Molecular Similarity. Int. J. Mol. Sci. 2022;23:1906. doi: 10.3390/ijms23031906.", "ArticleIdList": ["10.3390/ijms23031906", "PMC8837092", "35163824"]}, {"Citation": "Solt L.A., Burris T.P. Action of RORs and Their Ligands in (Patho)physiology. Trends Endocrinol. Metab. 2012;23:619\u2013627. doi: 10.1016/j.tem.2012.05.012.", "ArticleIdList": ["10.1016/j.tem.2012.05.012", "PMC3500583", "22789990"]}, {"Citation": "Zou H., Yang N., Zhang X., Chen H.-W. ROR\u03b3 is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. Biochem. Pharmacol. 2022;196:114725. doi: 10.1016/j.bcp.2021.114725.", "ArticleIdList": ["10.1016/j.bcp.2021.114725", "34384758"]}, {"Citation": "Zou H., Zou H., Yang Y., Yang Y., Shi Z., Shi Z., Wu X., Wu X., Liu R., Liu R., et al. Nuclear receptor ROR\u03b3 inverse agonists/antagonists display tissue- and gene-context selectivity through distinct activities in altering chromatin accessibility and master regulator SREBP2 occupancy. Pharmacol. Res. 2022;182:106324. doi: 10.1016/j.phrs.2022.106324.", "ArticleIdList": ["10.1016/j.phrs.2022.106324", "PMC10158160", "35750301"]}, {"Citation": "Wang Y., Huang Z., Chen C.Z., Liu C., Evans C.P., Gao A.C., Zhou F., Chen H.-W. Therapeutic Targeting of MDR1 Expression by ROR\u03b3 Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs. Mol. Cancer Ther. 2020;19:364\u2013374. doi: 10.1158/1535-7163.MCT-19-0327.", "ArticleIdList": ["10.1158/1535-7163.MCT-19-0327", "31712394"]}, {"Citation": "Kojetin D.J., Burris T.P. REV-ERB and ROR nuclear receptors as drug targets. Nat. Rev. Drug Discov. 2014;13:197\u2013216. doi: 10.1038/nrd4100.", "ArticleIdList": ["10.1038/nrd4100", "PMC4865262", "24577401"]}, {"Citation": "Zhou X., Chen H., Wei F., Zhao Q., Su Q., Lei Y., Yin M., Tian X., Liu Z., Yu B., et al. The Inhibitory Effects of Pentacyclic Triterpenes from Loquat Leaf against Th17 Differentiation. Immunol. Investig. 2020;49:632\u2013647. doi: 10.1080/08820139.2019.1698599.", "ArticleIdList": ["10.1080/08820139.2019.1698599", "31795780"]}, {"Citation": "Tian X., Tang L., Wei F., Chen H., Sheng L., Yang Y., Zhou X., Li Y., Xu X., Zhang B., et al. Pentacyclic triterpene compounds from loquat leaves reduce skin inflammation and epidermal hyperplasia in psoriasis via inhibiting the Th17 cells. Mol. Immunol. 2021;132:30\u201340. doi: 10.1016/j.molimm.2021.01.019.", "ArticleIdList": ["10.1016/j.molimm.2021.01.019", "33540227"]}, {"Citation": "Fujita-Sato S., Ito S., Isobe T., Ohyama T., Wakabayashi K., Morishita K., Ando O., Isono F. Structural Basis of Digoxin That Antagonizes ROR\u03b3t Receptor Activity and Suppresses Th17 Cell Differentiation and Interleukin (IL)-17 Production. J. Biol. Chem. 2011;286:31409\u201331417. doi: 10.1074/jbc.M111.254003.", "ArticleIdList": ["10.1074/jbc.M111.254003", "PMC3173075", "21733845"]}, {"Citation": "Lamers C., Schubert-Zsilavecz M., Merk D. Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists. Curr. Top. Med. Chem. 2014;14:2188\u20132205. doi: 10.2174/1568026614666141112103516.", "ArticleIdList": ["10.2174/1568026614666141112103516", "25388533"]}, {"Citation": "Sun L., Cai J., Gonzalez F.J. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2021;18:335\u2013347. doi: 10.1038/s41575-020-00404-2.", "ArticleIdList": ["10.1038/s41575-020-00404-2", "33568795"]}, {"Citation": "Jiang L., Zhang H., Xiao D., Wei H., Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Comput. Struct. Biotechnol. J. 2021;19:2148\u20132159. doi: 10.1016/j.csbj.2021.04.029.", "ArticleIdList": ["10.1016/j.csbj.2021.04.029", "PMC8091178", "33995909"]}, {"Citation": "Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362\u20131365. doi: 10.1126/science.284.5418.1362.", "ArticleIdList": ["10.1126/science.284.5418.1362", "10334992"]}, {"Citation": "Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science. 1999;284:1365\u20131368. doi: 10.1126/science.284.5418.1365.", "ArticleIdList": ["10.1126/science.284.5418.1365", "10334993"]}, {"Citation": "Zhang Y., Lee F.Y., Barrera G., Lee H., Vales C., Gonzalez F.J., Willson T.M., Edwards P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA. 2006;103:1006\u20131011. doi: 10.1073/pnas.0506982103.", "ArticleIdList": ["10.1073/pnas.0506982103", "PMC1347977", "16410358"]}, {"Citation": "Pellicciari R., Costantino G., Fiorucci S. Farnesoid X receptor: From structure to potential clinical applications. J. Med. Chem. 2005;48:5383\u20135403. doi: 10.1021/jm0582221.", "ArticleIdList": ["10.1021/jm0582221", "16107136"]}, {"Citation": "Shi X., Chen Y., Zhou T., Wang J., Xu X., Chen L., Hu L., Shen X. HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1\u03b1 promoter. Metabolism. 2018;85:126\u2013138. doi: 10.1016/j.metabol.2018.03.016.", "ArticleIdList": ["10.1016/j.metabol.2018.03.016", "29577938"]}, {"Citation": "Festa C., Finamore C., Marchian\u00f2 S., Di Leva F.S., Carino A., Monti M.C., del Gaudio F., Ceccacci S., Limongelli V., Zampella A., et al. Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists. ACS Med. Chem. Lett. 2019;10:504\u2013510. doi: 10.1021/acsmedchemlett.8b00534.", "ArticleIdList": ["10.1021/acsmedchemlett.8b00534", "PMC6466555", "30996787"]}, {"Citation": "Mudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H., Kipnes M., Adorini L., Sciacca C.I., Clopton P., Castelloe E., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574\u2013582.e1. doi: 10.1053/j.gastro.2013.05.042.", "ArticleIdList": ["10.1053/j.gastro.2013.05.042", "23727264"]}, {"Citation": "Sun Y., Zhang W., Li N., Guo S., Gao L., Ge N. Effect of Ursolic Acid Extracted from Hippophae rhamnoides L. on FXR Signaling Pathway in Liver of Rats with Alcoholic Liver Injury. Sci. Technol. Food Ind. 2023;44:363\u2013370. doi: 10.13386/j.issn1002-0306.2022040305.", "ArticleIdList": ["10.13386/j.issn1002-0306.2022040305"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "10", "Day": "6"}, {"Year": "2023", "Month": "10", "Day": "17"}, {"Year": "2023", "Month": "10", "Day": "18"}, {"Year": "2023", "Month": "10", "Day": "28", "Hour": "11", "Minute": "45"}, {"Year": "2023", "Month": "10", "Day": "28", "Hour": "11", "Minute": "44"}, {"Year": "2023", "Month": "10", "Day": "28", "Hour": "1", "Minute": "8"}, {"Year": "2023", "Month": "10", "Day": "19"}], "PublicationStatus": "epublish", "ArticleIdList": ["37893218", "PMC10604592", "10.3390/biomedicines11102845", "biomedicines11102845"]}}], "PubmedBookArticle": []}